National Coverage Determination (NCD 90.3): Chimeric Antigen Receptor (CAR) T-cell Therapy
This article informs you that effective for claims with dates of service on or after August 7, 2019, the Centers for Medicare & Medicaid Services (CMS) covers autologous treatment for cancer
with T-cells expressing at least one Chimeric Antigen Receptor (CAR) when administered at healthcare facilities enrolled in the Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategies (REMS) and meets specified FDA conditions.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: November 17, 2020
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.